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Abstract
CD36 is a platelet membrane glycoprotein whose engagement with oxidized low-density
lipoprotein (oxLDL) results in platelet activation. The CD36 gene has been associated with
platelet count, platelet volume, as well as lipid levels and CVD risk by genome-wide associa-
tion studies. Platelet CD36 expression levels have been shown to be associated with both
the platelet oxLDL response and an elevated risk of thrombo-embolism. Several genomic
variants have been identified as associated with platelet CD36 levels, however none have
been conclusively demonstrated to be causative. We screened 81 expression quantitative
trait loci (eQTL) single nucleotide polymorphisms (SNPs) associated with platelet CD36
expression by a Massively Parallel Reporter Assay (MPRA) and analyzed the results with a
novel Bayesian statistical method. Ten eQTLs located 13kb to 55kb upstream of the CD36
transcriptional start site of transcript ENST00000309881 and 49kb to 92kb upstream of tran-
script ENST00000447544, demonstrated significant transcription shifts between their minor
and major allele in the MPRA assay. Of these, rs2366739 and rs1194196, separated by
only 20bp, were confirmed by luciferase assay to alter transcriptional regulation. In addition,
electromobility shift assays demonstrated differential DNA:protein complex formation
between the two alleles of this locus. Furthermore, deletion of the genomic locus by
CRISPR/Cas9 in K562 and Meg-01 cells results in upregulation of CD36 transcription.
These data indicate that we have identified a variant that regulates expression of CD36,
which in turn affects platelet function. To assess the clinical relevance of our findings we
used the PhenoScanner tool, which aggregates large scale GWAS findings; the results rein-
force the clinical relevance of our variants and the utility of the MPRA assay. The study dem-
onstrates a generalizable paradigm for functional testing of genetic variants to inform
mechanistic studies, support patient management and develop precision therapies.
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Author summary
Platelets are anucleate cells that are best known as regulators of vascular hemostasis and
thrombosis but also play important roles in cancer, angiogenesis, and inflammation.
CD36 is a platelet surface marker that can activate platelet in response to oxidized low
density lipoprotein (oxLDL). CD36 has been associated with numerous cardiovascular
traits in human including blood lipid levels, platelet count, and cardiovascular disease
prevalence in human genetic studies. Human variability in platelet CD36 levels are associ-
ated with the platelet response to oxLDL. However, the genetic mechanisms responsible
for the variability of CD36 levels are unknown. We examined 81 genetic variants associ-
ated with CD36 levels for functionality using a high-throughput assay. Of the ten variants
that were identified in that assay, one doublet, rs2366739 and rs1194196, were confirmed
using additional molecular and cellular assays. Deletion of the genomic region containing
rs2366739 and rs1194196 resulted in overexpression of CD36 in a cell culture system. This
finding indicates a control locus which can serve as a potential target in modulating CD36
expression and altering platelet function in cardiovascular disease.
Introduction
Cardiovascular disease (CVD) remains the number one cause of death globally [1]. Myocardial
infarctions (MI) are acute events in CVD which are frequently the proximal causes of death or
severe disability which are the result of platelet-rich thrombi [2]. Genome wide association
studies (GWASs) have identified numerous common genetic variants associated with the risk
of CVD and platelet function parameters, but these variants are usually not causative due to
the resolution of the genotyping platforms used and genetic linkage. One of the genes identi-
fied by GWAS as associated with platelet count, lipid levels. and CVD is the platelet oxidized
LDL (oxLDL) receptor, CD36 [3–5].
CD36 is a transmembrane protein belonging to the class B scavenger receptor family
expressed in platelets and variety of other cells [6–8]. It binds to many ligands such as oxidized
phospholipids (oxPL) and oxidized low-density lipoprotein (oxLDL) long-chain fatty acids
[9]. In platelets, CD36 interaction with oxLDL and thrombospondin-1 (TSP1) triggers MAP
and Src family kinase dependent signaling events leading to platelet activation, [10, 11] which
also lead to increase in P-selectin expression and αIIbβ3 activation [10]. Deletion of CD36 in
mice fed a high fat diet results in attenuation of the pro-thrombotic state and platelet hyper-
activity [10].
CD36 deficiencies have been identified which result in increased risk of cardiomyopathy,
hyperlipidemia and insulin resistance [12–15]. In type I deficiency, monocytes and platelets
lack CD36 expression, whereas in type II only platelets lack CD36 expression. CD36 deficiency
is more frequent in black and Asian populations. Our platelet transcriptomic data also show
that platelet CD36 RNA levels are lower in the black population and in women [16, 17]. The
molecular mechanisms behind CD36 deficiency have been attributed to variants causing
defects in protein maturation or frameshift, resulting in an absence of protein [14, 18].
Among subjects without CD36 deficiency, there is a wide range of platelet CD36 surface
expression and the level of CD36 correlated with reactivity to oxLDL [19]. Many genetic vari-
ants have already been reported to be associated with platelet CD36 expression, however, these
variants span a large linked genomic area and no functional analysis has been carried out [19,
20]. We have previously reported platelet expression Quantitative Trait Loci (eQTLs) that
associate single nucleotide polymorphisms (SNPs) with platelet RNA levels, indicating genetic
MPRA reveals CD36 expression functional variants
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008287 July 25, 2019 2 / 20
Competing interests: The authors have declared
that no competing interests exist.
variability effecting gene expression [21]. CD36 is one of the 612 platelet-expressed RNAs
whose abundance has significant genotypic associations. 81 eQTL SNPs located within a +/-
100kb window of the CD36 gene are associated with platelet CD36 mRNA levels at a signifi-
cance of P<1x10-6, spanning a range of 118kb.
We hypothesized that a parallel screening method would be more efficient and cost-effective
to identify causal variants instead of a one-at-a-time approach. We used a massively parallel
reporter assay (MPRA) to screen the 81 platelet eQTLs associated with CD36 mRNA. We devel-
oped new statistical methods for MPRA analysis, and we were able to identify rs2366739 and
rs1194196 as functional variants that alter transcriptional regulation. We further tested these
MPRA-functional variants, showing significant transcription shift between the reference and
alternate alleles by luciferase assays, electromobility shift assays (EMSA) and using CRISPR/Cas
edited stable cell lines. Finally, we used the Phenoscaner GWAS aggregation tool to reinforce
the clinical relevance of our functional variants. Using these approaches, we have identified
genetic variants that modulate platelet CD36 expression and have clinical associations.
Results
Landscape of CD36 variants
We have previously published the results of a cis-eQTL analysis of platelet gene expression
[21]. SNPs found to be associated with platelet CD36 mRNA expression are indicated by dia-
monds on the Manhattan plot in Fig 1. Ghosh et al. have also looked for associations between
CD36 SNPs and CD36 protein expression [19]. SNPs identified in that report are indicated in
Fig 1 by squares, and SNPs that were identified both by our eQTL study and Ghosh et al.
are indicated by upside-down triangles. Several CD36 SNPs have been identified in GWAS
studies to associate with platelet count or volume. The GWAS-identified SNPS rs6961069,
rs13236689, rs2177616, and rs11764390 are also platelet CD36 eQTLs and are indicated by tri-
angles in Fig 1 [4, 22, 23]. rs139761834 (Fig 1, circle) was identified by GWAS but not by
eQTL analysis [23]. The genomic region containing these variants encompasses the 5’ end of
the CD36 gene and upstream sequence and is highly linked as indicated by the linkage disequi-
librium plot in the bottom panel of Fig 1. Given that most data on CD36 deficiency and expres-
sion has been obtained from Japanese subjects, D’ values were calculated using the 1000
Genomes JPT population. This strong linkage makes identification of the functional variant
difficult, and therefore functional analysis requires experimental testing of individual SNPs.
The large genomic span and the number of CD36 phenotype-linked variants necessitated a
highly parallel approach for functional testing.
Massively parallel reporter assay identifies CD36 SNPs with allelic
difference in CD36 gene expression
We generated a library of plasmids in which a unique 10bp barcodes located downstream to a
luciferase cassette were transcribed under the control of a 150bp genomic fragment containing
a CD36 platelet eQTL SNP. Each allele of each variant is associated with 40 unique barcodes in
order to give high statistical power for detecting variant function despite variation in the NGS
outputs. Successful conduction of a MPRA experiment requires high transfection efficiency to
allow for sufficient expression of barcode diversity. We compared the RNA-seq gene expres-
sion profiles of several hematopoietic cell lines (derived from ArrayExpress (https://www.ebi.
ac.uk/arrayexpress/) accession number E-MTAB-4101) to RNA-Seq data from cultured mega-
karyocytes (derived from Blueprint Epigenome Data [24]). All comparisons were significant at
P<0.0001 and the Spearman correlation coefficient ranged from 0.658 to 0.720 (Table 1). We
MPRA reveals CD36 expression functional variants
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ultimately chose to utilize K562 cells due to their myelogenous origin, transfection efficiency,
the comparable expression profile similarity to other cell lines and megakaryocytes, and their
prior successful use in MPRA experiments [25]. Transcription activity driven by each variant
was then measured by quantifying RNA barcodes output after they have been “normalized” or
jointly modeled against the plasmid DNA library barcode inputs. An overview of MPRA pro-
tocol is presented in Fig 2.
Fig 1. Genomic context of CD36 variants. (Upper) Manhattan plot of CD36 variants identified as platelet eQTLs only
(diamonds), associated with CD36 surface levels (squares), GWAS-implicated (circle), eQTLs and CD36 surface level associated
(upside down triangle), eQTLs and associated with GWAS-implicated (triangle), eQTLs and functional in MPRA assay (X’s), or
eQTLs functional in MPRA assay and validated by luciferase (squared X).–log10 P-values are significance of eQTL association, if
available, or from CD36 surface level association. GWAS-implicated variant (circle) is associated with platelet count (P = 2 x
10−17) and vertical position does not represent significance. (Lower) LD-plot of genomic locus with D’ values calculated with 1000
genomes JPT (Japanese) population.
https://doi.org/10.1371/journal.pgen.1008287.g001
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We employed two statistical methods to analyze the result of the MPRA: a traditional
method that involves computing variant activities defined by a ratio transformation of mRNA
to DNA input and a second Bayesian method. The traditional method normalizes the counts
for sample depth, removes barcodes with low representation in the plasmid library, and com-
putes the activity as log mRNADNA
  �
of each barcode in each allele in each transfection, and then uses
a t-test and false discovery rate correction to compare the mean activity levels of alleles for
each SNP. This approach yields 14 hits with Q< .05, including nine of the 10 controls
(Table 2; Fig 3A and S1 Fig) and five CD36 SNPs: rs2366739, rs940542, rs1093831, rs11464747,
and rs6467258 (Table 2; Fig 3B and S1 Fig). MPRA activities can occasionally defy the normal-
ity assumption underlying the t-test,[26] so we also employed the non-parametric Mann-
Whitney U-test, under the same frequentist methodologic paradigm as the t-test approach.
Analyzing the transcription activity level with a U-test revealed an additional four significant
variants, rs1194196, rs6961069, rs819456, and rs819457 (Table 2; Fig 3C and S1 Fig).
We sought to avoid two statistical limitations that lead to information and power loss in the
MPRA experiment using the traditional analysis approach. First, transforming the data with a
ratio removes the ability to model systematic effects of the DNA and RNA libraries. Second, dis-
carding barcodes with low or 0 counts discards data that may be informative. Therefore, we also
employed a Bayesian count model of the data generating process that models the NGS reads of
each barcode observed from sequencing the plasmid library and from each transfection experi-
ment as arising from coupled negative binomial distributions. The means of the negative bino-
mial distributions are proportional to the depth of the sequencing of each sample and, in the case
of RNA samples, the mean of the barcode’s DNA read count. Empirical gamma priors on the
negative binomial parameters were estimated marginally across all SNPs in the assay. The log dif-
ference in the depth- and DNA-normalized RNA means gives a quantity comparable to the dif-
ference in mean activity (i.e. the ratios) analyzed under the t-test-based method. Thus, this model
provides a posterior on transcription shift for each SNP after directly accounting for more
sources of variation and more data from the MPRA experiment than the traditional approach.
We identify a SNP in question as a functional hit if a 95% credible interval for the posterior distri-
bution of the transcription shift excludes 0. This process yields 19 hits, including the same nine of
the ten controls and ten CD36 SNPs, the nine listed above plus an additional variant, rs1093833
(Table 2; Fig 3D and S1 Fig) that was not identified by the frequentist approaches. As shown in
Fig 1, (MPRA positive hits indicated by X’s) these SNPs are in high LD with one another, indicat-
ing close physical proximity in what is likely the regulatory region of the CD36 gene. The com-
plete analysis results of the tested MPRA variants and controls is given in S1 and S2 Tables.
Validation of differential enhancer activity of rs2366739-rs1193196 locus
To verify the transcription shifts identified by the MPRA, we tested three of the controls, the
two most significant MPRA hits by t-test (rs2366739 and rs940542), the additional two most
Table 1. Comparison of cell line gene expression to megakaryocytes.
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significant MPRA hits identified by U-test (rs1193196 and rs819456), and the additional signif-
icant MPRA hit identified by Bayesian analysis (rs1093833) by reporter assay. Reporter plas-
mids containing reference or alternate alleles of the eQTLs were transfected into K562 cells
and assayed after 48 hours for luciferase and β-gal expression. We first investigated the activity
Fig 2. Design of the massively parallel reporter assay. A library of oligonucleotides was designed and synthesized containing
CD36 eQTL SNPs surrounded by 150bp of genomic context 5’ to a KpnI/XbaI linker used to insert a minimal promoter-
luciferase cassette derived from pNL3.2. 3’ to the linker is a unique 10bp barcode. SfiI restriction sites generated by PCR were
used to clone the oligo into the pMPRA1 backbone vector. The plasmid library was transfected into K562 cells and 48 hours
RNA was harvested. Barcodes from the harvested RNA and plasmid DNA library was quantified by NGS.
https://doi.org/10.1371/journal.pgen.1008287.g002
Table 2. MPRA-functional CD36 variants.
Control/CD36 SNP Transcription Shift t-test u-test Bayesian Model
P-Value Q-value� P-Value Q-Value� Posterior Mean 95% Credible Interval†
URUOS -2.55525 1.94E-131 1.76E-129 2.08E-38 1.89E-36 -2.44298 -2.616 : -2.267
PKRRE5 -1.00354 9.86E-73 4.49E-71 1.41E-37 6.40E-36 -1.11463 -1.282 : -0.944
PKRRE3 -0.87213 1.24E-71 3.77E-70 4.44E-37 1.35E-35 -1.01771 -1.183 : -0.848
ALAS23 -2.08592 8.95E-62 2.04E-60 5.82E-33 8.82E-32 -2.00429 -2.276 : -1.703
ALAS22 -2.413 2.53E-57 3.83E-56 1.11E-28 1.12E-27 -2.48037 -2.838 : -2.114
ALAS21 -2.10623 6.23E-57 8.10E-56 1.52E-32 1.97E-31 -2.00922 -2.33 : -1.699
PKRRE4 -0.89499 2.37E-56 2.70E-55 7.73E-36 1.76E-34 -0.93448 -1.097 : -0.769
PKRRE1 -0.69606 7.38E-39 7.46E-38 2.57E-30 2.92E-29 -0.75478 -0.924 : -0.59
PKRRE2 -0.26871 1.76E-06 1.45E-05 1.47E-08 1.34E-07 -0.37922 -0.698 : -0.055
HBG2 0.06142 4.96E-01 7.28E-01 7.87E-01 8.97E-01 -0.01277 -0.231 : 0.214
rs2366739 -1.04532 6.87E-59 1.25E-57 1.41E-35 2.57E-34 -1.13049 -1.295 : -0.955
rs940542 -0.2785 2.56E-07 2.33E-06 6.51E-07 5.39E-06 -0.29285 -0.481 : -0.12
rs1093831 -0.273 1.07E-04 8.09E-04 7.70E-05 5.84E-04 0.10111 -0.113 : 0.315
rs6467258 0.22024 6.72E-03 4.37E-02 7.47E-04 5.23E-03 -0.05448 -0.259 : 0.16
rs1194196 -0.23346 1.21E-02 6.45E-02 1.07E-03 6.93E-03 -0.08582 -0.271 : 0.111
rs11464747 0.36056 1.02E-03 7.16E-03 1.70E-03 1.03E-02 1.23996 0.962 : 1.518
rs819456 0.31541 3.05E-02 1.32E-01 2.68E-03 1.52E-02 0.46373 0.079 : 0.861
rs6961069 0.21993 1.14E-02 6.45E-02 2.90E-03 1.55E-02 0.01234 -0.211 : 0.233
rs819457 0.18773 1.58E-02 7.58E-02 3.07E-03 1.55E-02 0.14833 -0.072 : 0.372
rs1093833 0.54135 1.04E-01 3.03E-01 1.23E-01 3.12E-01 1.00913 0.271 : 1.764
� Significant Q-values are highlighted (Q<0.05).
†Significant credible intervals are highlighted (Interval does not contain 0).
https://doi.org/10.1371/journal.pgen.1008287.t002
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of each control sequence (ALAS2-1, 2 and 3) containing original or disrupted GATA1 binding
site. As predicted and shown previously the sequences with original binding site exhibited
Fig 3. Results of MPRA assay of CD36 eQTL SNPs. (A) MPRA activity of positive control constructs. (B) MPRA
activity of CD36 eQTL SNPs with significant transcription shifts identified by T-Test. (C) Additional CD36 variants
with significant transcription shifts identified by U-Test. (D) Additional CD36 SNP with significant MPRA
transcription shift identified by Bayesian analysis.
https://doi.org/10.1371/journal.pgen.1008287.g003
MPRA reveals CD36 expression functional variants
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more enhancer like activity by luciferase expression than the sequence with disrupted (Alt)
binding site (Fig 4A) [25].
Because eQTLs rs2366739 and rs1194196 are within 21 base pairs of each other and in high
linkage disequilibrium we constructed single oligos which contains either reference (T-A for
rs2366739-rs1194196) or alternate alleles (C-T) for both eQTLs. These genotypes account for
96% of the observed haplotypes from all populations. Out of the five tested constructs,
rs819456 and rs2366739-rs1194196 showed significant transcriptional difference between
their reference vs alternate allele as depicted by the luciferase levels (Fig 4B). The
rs2366739-rs1194196 results are in agreement with our platelet eQTL data and whole blood
eQTL data from Jansen et al. that indicate that the ‘C’ allele of rs2366739 is associated with
lower levels of CD36 mRNA (Fig 4C) [21, 27]. Overall expression from the rs819456 constructs
was higher than other constructs but the direction of the difference between alleles (higher in
the reference, Fig 4B) was opposite to that of the MPRA results (lower in the reference (Fig
3B)). Finally, to test the transcriptional activity in a system more closely related to megakaryo-
cytes, we repeated the luciferase assay of the rs2366739-rs1194196 construct in Meg-01 chronic
myelogenous leukemia cells. In this system, the difference in transcriptional potency between
the two alleles was consistent with the results in K562 cells showing an approximate 20%
reduction in transcription between the two alleles (Fig 4D).
rs2366739 has been described as an CD36 eQTL not just in our platelet data but in whole
blood data from Võsa et al. (P = 1.3 x 10−267) [28]. In addition rs2366739 has been associated
with DNA methylation levels (P = 6.51 x 10−81) [29]. These results in addition to the high sig-
nificance and directional agreement of the rs2366739-rs1194196 luciferase and MPRA results
lead us to pursue the rs2366739-rs1194196 locus in further tests.
Differential protein binding between reference and alternate allele of
rs2366739 and rs1194196
One of the mechanisms by which gene expression is regulated is the binding of transcription
factors to regulatory elements. To test if the difference in transcription between TA and CT
alleles of the rs2366739-rs1194196 constructs is due to alteration in transcription factor bind-
ing affinity, we performed an electrophoretic mobility shift assay (EMSA) to compare binding
of K562 nuclear extracts to probes derived from the two different haplotypes. The results show
formation of a DNA:protein complex with twice as much affinity to the TA genotype probe
than to the CT genotype probe (Fig 5).
In vivo validation of rs2366739-rs1194196 locus as CD36 regulatory
element
To confirm the locus containing rs2366739 and rs1194196 regulates CD36 expression, we gen-
erated K562 cell lines with deletion of 573 basepairs containing this region using CRISPR/
Cas9. The deletion was confirmed with PCR comparing clones transfected with sgRNAs to
those transfected with vectors with no sgRNA (Fig 6A, lane C). Clones labeled WT do not not
contain a deletion whereas clones labeled KO were successfully altered. To determine the effect
of this deletion on CD36 RNA expression, CD36 transcript levels were measured by qRT-PCR.
In the cells with the rs2366739-rs1194196 locus removed, CD36 mRNA was ~13 times greater
than the clones with the region intact (Fig 6C). We also analyzed the effect of this deletion in
Meg-01 cells. We were only able to obtain clones containing heterozygous knockouts (Fig 6B).
However, like in K562 cells, this resulted in a ~39-fold increase in CD36 mRNA levels (Fig
6C). This supports the evidence that this genomic region identified by MPRA regulated
expression of the CD36 gene.
MPRA reveals CD36 expression functional variants
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Assessment of clinical significance
To assess the clinical relevance of our findings we used the PhenoScanner tool, which aggre-
gates large scale GWAS findings. We re-identified the rs2366739 variant in the CD36 associa-
tions and we found it to be strongly associated with platelet volume and count but not with
phenotypes unrelated to platelet activity. These results reinforce the clinical relevance of our
variants and the utility of the MPRA assay.
Discussion
The expression of CD36 has been actively studied since the identification of a deficiency in
healthy Japanese and US donors [30]. CD36 deficiency has been divided into two types: Type I
in which neither platelets nor monocytes express surface CD36 and Type II in which only
platelets lack expression [31]. Lack of CD36 leads to numerous cellular phenotypes including
Fig 4. Luciferase assay of MPRA-identified variants. (A) Relative luciferase activity of reporter vectors containing
control (WT) or mutated (Mut) GATA1 sites. (N = 3) Significance by one-sample T-test (B) Luciferase activity
normalized to β-gal activity of MPRA-functional CD36 variants in K562 cells. Reference (Ref) and Alternate (Alt) alleles
for each variant is indicated. (C) Platelet eQTL analysis indicated that platelet CD36 mRNA levels are associated with
rs2366739 genotype (P = 2 x 10−8). Line = mean expression, Box = 25th to 75 interquartile range (IQR), Whiskers = 1.5 x
IQR. (D) Luciferase activity normalized to β-gal activity of reporter vectors containing the rs2366739-rs1194196 locus
transfected into Meg-01 cells. (B,D) N = 3 to 5 Significance by two-sample T-test. � <0.05, �� < 0.01.
https://doi.org/10.1371/journal.pgen.1008287.g004
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defective uptake of long chain fatty acids by the myocardium[32, 33] and altered lipid profiles
[34, 35]. Lack of CD36 has also been associated with altered foam cell formation in both
humans and mice [36, 37]. Even in non-deficient patients a wide range of CD36 expression
has been observed and this variation has been associated with the platelet response to oxLDL
[19, 38].
Five genetic causes of type I deficiency have been identified, two of which lead to alterations
in post-translation modification or surface trafficking, the other three which lead to frame-
shift mutations [18, 39–41]. The basis of type II deficiency remains unclear. Mechanisms
behind the broad range of non-deficient expression has been explored previously. For example
Fig 5. rs2355739-rs1194196 variants alter protein:DNA interactions. (A) Electromobility shift assay using probes
containing 70bp of genomic sequence containing SNPs rs2355739 and rs1194196. Digoxin-labeled Probes were
incubated with K562 cell nuclear extract where indicated, resolved by gel electrophoresis, and imaged with anti-
digoxin antibodies. Arrow indicated specific complex formed by protein:DNA interactions. (B) Quantification of
DNA:protein complex by densitometry. (N = 3) Significance by one-sample T-test.
https://doi.org/10.1371/journal.pgen.1008287.g005
Fig 6. Deletion of the rs2355739-rs1194196 locus increased CD36 expression. Deletion of the rs2355739-rs1194196 locus in (A) K562 and
(B) Meg-01 cells by CRISPR/Cas9 was validated by PCR using primers flanking the deleted section. WT clones did not contain a deletion
while KO clones contained the deletion. (C) qRT-PCR of CD36 mRNA indicated that the wildtype (WT) K562 and Meg-01 clones contained
less CD36 RNA than KO clones lacking the rs2355739-rs1194196 locus (KO).
https://doi.org/10.1371/journal.pgen.1008287.g006
MPRA reveals CD36 expression functional variants
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Ghosh et al. previously identified a number of SNPs that are associated with platelet CD36 lev-
els and Masuda explored surface levels in individuals heterozygous for the deficiency muta-
tions mentioned above [19, 38]. However, given the tightly linked nature of the locus (Fig 1),
neither of these studies identified functional variants.
Our data presented here represents the first comprehensive analysis and testing of genetic
variants associated with CD36 mRNA expression. We tested 81 variants associated with plate-
let CD36 mRNA levels, some of which overlap with variants previously associated with surface
levels, by MPRA. Of these variants, rs2366739 and rs1194196, which are within 21 base pairs
of each other, were identified by MPRA and validated by (1) altering expression of a linked
reporter gene, (2) altering protein binding in a gel-shift assay, and (3) altering endogenous
CD36 expression when the locus containing these variants was deleted by genome editing.
Importantly, rs2366739 has previously been associated with both platelet count (P = 9.13 x
10−10) and platelet volume (P = 5.27 x 10−11) [22]. Taken together, we found that the MPRA
analysis refined the region of CD36 responsible for gene expression and within this region the
MPRA distinguished specific GWAS hits for platelet-associated phenotypes. This result empha-
sizes the utility of the MPRA to clarify and refine association analyses in highly linked regions.
The analysis methods employed for our CD36 MPRA are another important contribution
of this work. We applied t- and U-tests that have been employed in prior MPRA studies, but
we also introduced a new and more comprehensive Bayesian approach. Our new method reca-
pitulates the findings of the prior methods, but also identifies a variant that was missed by the
prior approaches. A key advantage of our new statistical method is a generative stochastic
model that probabilistically accounts for the discrete nature of NGS count data as well as
sources of variation in the MPRA experiment without having to discard zero counts. S4 Fig
shows a Kruschke diagram of the generative process considered by the model. The sources of
variation addressed include variation in the barcode abundances in the cDNA library as well
as other factors. Furthermore, the use of empirical priors provides estimate shrinkage; noisy
parameter estimates are shrunken towards more moderate levels observed throughout the rest
of the assay. This process helps eliminate false positives without the heavy statistical burden of
multiple testing correction procedures like false discovery rates. We have previously studied
the statistical power of MPRA experiments using the standard approaches [26]. Although the
prior methods were at least partially successful to analyze MPRA data, our Bayesian model
appears both practical and more powerful. Therefore, our paper demonstrates effective statisti-
cal improvements to analysis of MPRA studies. This approach may be particularly important
in larger scale genome wide MPRA studies, and more work is warranted to improve the cost-
effectiveness as well as the discovery potential of MPRA assays.
One of the weaknesses of this study is that we have been unable to identify the DNA-bind-
ing protein factor whose binding is altered by the variants. The rs2366739-rs1194196 is located
in a genomic locus that contains ChIP-Seq signals for Histone H3K27 acetylation and is in a
DNA hypersensitive region in primary and cultured hematopoietic stem cells.[42] However
ChIP-Seq data of specific transcription factors in CD34 cells and megakaryocytes is limited
and we have not been able to identify a sequence-specific factor bound to the region. We have
analyzed the sequence using the transcription factor binding prediction algorithm JASPAR
[43] and found predictions for the well-studied megakaryocytic transcription factors GATA1/
2/3 and Gfi1/Gfi1b on the TA haplotype but not CT.[44, 45] Interestingly these two transcrip-
tion factor families, GATA and Gfi1, have opposite functions; GATA factors are transcrip-
tional activators while Gfi1 and Gfi1b are transcriptional repressors. This suggests that these
two factors may regulate CD36 expression in a complex manner that is affected by genotype.
The dual nucleotide changes assayed in Figs 4 and 5 indicate that the TA haplotype results
in higher transcriptional activity and an enhancement of protein binding, suggesting that a
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positive regulatory factor is more readily bound to the TA haplotype. However, deletion of the
locus resulted in enhanced CD36 expression in both K562 and Meg-01 cells, suggesting a nega-
tive regulatory activity also exists. There are differences between these experiments which can
contribute to understanding our observations: The luciferase and EMSA experiments are per-
formed in vitro using 70bp of genomic sequence surrounding rs2366739- rs1194196, either by
itself as an EMSA probe or cloned into a luciferase vector. The genomic deletion is a 573bp
deletion of DNA in a genomic chromatin context. In the genomic context, the locus is located
56 kbp and 92 kbp from the two transcriptional start sites of CD36. In the plasmid context, the
transcription start site is immediately downstream from the cloned fragment. We hypothesize
that additional negative regulatory factors bind to genomic DNA, outside the limited context
used in MPRA and the 70bp fragment tested by luciferase and EMSA (S2 Fig). Therefore, in
experimental conditions containing only the 70bp region, a positive regulatory factor deter-
mines transcriptional/binding activity. But in the genomic context, deletion of the 573bp frag-
ment results in the loss of both positive and negative factors, resulting in a net increase in
transcription, perhaps driven by enhancers more proximal to the promoter. More work is
required to further investigate this hypothesis.
Currently, more human genetic studies are moving beyond associations of genotypes with
phenotypes to seeking the molecular mechanisms behind the variants responsible for the
observed traits. Mechanistic understanding of genetic variants will provide better understand-
ing of the observed physiology, allow for more precise biomarkers, and identify potential new
therapeutic targets. Given the large number of variants potentially associated with a trait in
highly linked genomic regions such as CD36, high-throughput methods are necessary to effi-
ciently test and identify functional polymorphisms in an unbiased manner. Our identification
of the genetic locus responsible for inter-individual variation in non-deficient CD36 expres-
sion opens new areas of investigation into the link between this locus and platelet function,
serum lipid levels, and atherosclerosis.
Materials and methods
Ethics statement
K562 and Meg-01 cells were obtained from the American Tissue Culture Collection (ATCC)
Cell culture
K562(CCL-243) and Meg-01 (CRL-2021) cells from ATCC were maintained in RPMI 1640
media (Invitrogen, CA 10-040-cv) containing penicillin-streptomycin and 10% FBS.
MPRA
The MPRA design was based on the method previously published (A graphical summary is
presented in Fig 2) [46]. To design the CD36 MPRA library, we used a p-value threshold of
p< 1x10-6 to select the expression quantitative trait loci (eQTLs) most highly associated with
CD36 expression in the PRAX study surrounded by 150bp of hg38 genomic context [21]. After
discarding 5 eQTLs that contained digestion sites for restriction enzymes used in the library
preparation in their genomic context, this yielded a set of 81 CD36 SNPs to assay. We also
included 10 SNPs previously identified in the literature as directly affecting ALAS2, HBG2,
PKRRE, and URUOS expression as a set of positive controls (S3 Table) [47, 48]. We synthesized
40 oligonucleotide replicates per allele(Agilent, Santa Clara, CA), each uniquely tagged with
inert 10bp barcodes which followed the design criteria stipulated in Melnikov et al. [49]. The
library of oligonucleotides was amplified using emulsion PCR and the primers 5’-
MPRA reveals CD36 expression functional variants
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008287 July 25, 2019 12 / 20
TGCTAAGGCCTAACTGGCCAG-3’ and 5’-CTCGGCGGCCAAGTATTCAT-3’ which also
added additional sequence containing SfiI restriction enzyme sites to each end. After each
oligo was directionally cloned into pMPRA1 (Addgene, Cambridge, MA) using the SfiI sites, a
minimal promoter and luciferase cassette derived from pNL3.2 (Promega, Madison, WI) was
inserted in between the genomic sequences and the barcode using KpnI and XbaI sites. This
library of plasmids was transfected into K562 cells and then RNA was harvested 48 hours later.
After reverse transcription with a polyT primer, three separate amplifications of the cDNA
were performed to generate RNA sequencing libraries. The barcodes contained in the MPRA
plasmid library were subjected to two separate amplifications to generate DNA sequencing
libraries. RNA and plasmid barcode expression was quantified by next generation sequencing
on an Illumina MiSeq in the Children’s Hospital of Philadelphia sequencing core. After extrac-
tion from the fastq files, barcodes with a quality of Q>30 at every base was counted. RNA bar-
code counts were analyzed in conjunction with the DNA barcode counts to control for
variances in barcode abundances introduced by library generation. Quality control data con-
cerning the sequencing libraries are presented in S4 Table and Fig 7 and S3 Fig.
Both frequentist (t-tests and U-tests) and Bayesian analyses were applied to identify variants
that caused alterations to transcription activity by use of RNA-to-DNA ratios to examine allelic
differences. Analysis of the barcode counts proceeds by computing the MPRA activity of each
barcode as the log-ratio of the depth-normalized RNA counts to depth-normalized DNA
counts and each variant’s corresponding “transcription shift”. The transcription shift of a vari-
ant is defined as the difference in activity between the alternate and reference alleles.
The application of traditional frequentist tests to MPRA activities has been previously
described [25, 26]. The novel Bayesian analysis models the barcode count data using negative
binomial distributions with empirical gamma priors (Fig 8), this analysis method provides
greater sensitivity than traditional methods while retaining specificity.
Luciferase assay
We designed and ordered oligonucleotides (IDT-DNA, Coralville, IA) containing the candi-
date MPRA-functional SNPs and 40bp of flanking genomic sequence (S5 Table). The ampli-
fied sequence was inserted into nano-luciferase containing plasmid pNL3.2 (Promega,
Madison, WI) using HindIII and XhoI (ThermoFisher, Waltham, MA) restriction sites. The
sequence was confirmed by sequencing. Three independent preparations of reporter plasmids
and β-gal expression plasmids were cotransfected in K562 cells or Meg-01 cells and luciferase
assay was carried out after 48 hours using Nanoglo luciferase kit (Promega) and normalized to
ß-gal expression measured using assay reagent (ThermoFisher).
Electromobility assay (EMSA)
Nuclear extracts from K562 cells were isolated using the NE-PER Nuclear and Cytoplasmic
Extraction Kit (ThermoFisher). 70 base pair sequences containing either the reference alleles
for rs2366739 and rs1194196 (referred to as TA) or alternate alleles (referred to as CT) were
amplified by PCR using MPRA plasmid library as template. Digoxigenin (DIG) labeled nucle-
otides (Roche, Basel, Switzerland) were used to create amplified sequences with DIG labeled
base pairs. The sequences were purified by agarose gel electrophoresis and the QIAEX II Gel
Extraction Kit (Qiagen, Hilden, Germany).
10μg of nuclear extract was incubated with DIG labeled probes in buffer containing 10%
glycerol, 20 mM HEPES, 30 mM KCl, 30 mM NaCl, 3 mM MgCl2, 1 mM DTT. 1 μg of Poly
dI-dC was added to reduce nonspecific binding. The reaction was carried out for 30 mins on
ice. The sample was mixed with 10X orange loading dye (Licor, Lincoln, NE) and loaded on
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6% acrylamide gel and ran for 4–5 hours with 0.5% TBE buffer. The DNA-protein complex
was transferred on positively charged Biodyne nylon membrane (Pall Industries, Fort Wash-
ington, NY) using 0.5% TBE for 45 minutes. The membrane was incubated in blocking solu-
tion for 30 mins at RT, followed by Anti-Digoxigenin-AP antibody containing blocking
solution for 30 mins at RT. The membrane was then washed twice for 15 minutes each using
washing solution, visualized using chemiluminescence, and quantified.
Fig 7. Correlation of sequencing libraries. (A) Scatterplot of barcode counts showing the correlation between the two sequencing
samples prepared from the plasmid library. (B) A similar plot showing the expectedly lower correlation between one plasmid sample
and a cDNA sample. Because the barcodes need to go through a transcription step to be present in the cDNA sample, these counts are
inherently more noisy and less correlated with their plasmid barcode inputs. C) A heatmap showing the pairwise correlation values
between all five samples in the experiment.
https://doi.org/10.1371/journal.pgen.1008287.g007
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CRISPR-modified cell line generation
To generate genomic deletion mutants, the CRISPR/Cas9 system was used as previously
reported [50]. Two guide RNAs (sgRNA) flanking 573 base pairs containing rs2366739 and
rs1194196 were designed (IDT DNA). The design of sgRNA pairs for targeting and prediction
of off-target sites were based on online tools: CRISPR Design (http://crispr.mit.edu/) and CRIS-
POR (http://www.crispor.org)[51]. Two guide RNAs, 5’-TACCCCCATTGTATCTATCTAGG-
3’ and 5’- CTACAGTAAATACACTTGTCAGG -3’ were used to delete the 573 basepair region.
Pairs of complementary DNA oligos (IDTDNA, Coralville, IA) were individually phos-
phorylated with T4 polynucleotide kinase (NEB, Ipswitch, MA) and then annealed. Each DNA
oligo duplex had 5’ overhangs (forward: ACCG, reverse: AAAC) designed to be directly cloned
into the BbsI or BsaI-digested and dephosphorylated AIO-GFP(Cas9) vector using the Quick
Ligation Kit (NEB). The first and second sgRNA was cloned into the BbsI and BsaI sites,
respectively, and confirmed by colony PCR and sequencing. The plasmid was transfected in
K562 using Lipofectamine2000 (ThermoFisher) or Meg-01 with Nucleofection.(Lonza, Basel,
Switzerland). After 24 hours, the GFP positive cells were sorted by flow cytometry and individ-
ually seeded in a 96 well plate. Single colonies were expanded further and a cell line was estab-
lished from a single clone. Deletion was confirmed by PCR and sequencing.
Reverse transcription and quantitative real time PCR:
Total RNA was isolated using Trizol Reagent (ThermoFisher). 3μg total RNA was used for first
strand cDNA synthesis with the SuperScript III First-Strand Synthesis System (ThermoFisher).
Fig 8. Negative binomial mean parameter priors. Density functions of the empirically estimated gamma priors for (A) the
cDNA samples and (B) the plasmid library samples.
https://doi.org/10.1371/journal.pgen.1008287.g008
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To evaluate relative expression levels of mRNAs, we performed qRT-PCR with the Power
SYBR Green PCR master mix (Life Technologies, Carlsbad, CA) normalized to Actin. We car-
ried out real time PCR reaction and analyses in 384-well optical reaction plates using the
CFX384 instrument (Bio-Rad, Hercules, CA).
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